WBUHS PROF EXAM - COMPREHENSIVE ANSWERS

(As per Park's Textbook of Preventive and Social Medicine)

---

CHAPTER 1: CONCEPTS OF HEALTH, DISEASE & PREVENTION

---

Q1. Concepts of Primordial Prevention is more appropriately used in Non-communicable diseases - Justify (Jhargram GMC&H)

1. Nature of NCDs: NCDs like coronary heart disease, hypertension, diabetes, obesity, and cancers are caused by interplay of multiple risk factors (lifestyle, dietary, environmental). These risk factors are not present at birth but emerge due to societal/economic transitions.
2. Risk factor development pattern: In NCDs, risk factors (obesity, sedentary lifestyle, tobacco use, unhealthy diet) develop gradually over years before the disease manifests. Primordial prevention aims to prevent these risk factors from ever arising in a population.
3. Applicability example - CVD: In countries where CVD was rare (e.g., Japan in 1950s), the objective was to prevent the adoption of Western dietary and lifestyle patterns that are known CVD risk factors. This is primordial prevention.
4. Societal and policy approach: Primordial prevention operates at the population/community level through policy measures - nutrition policies, tobacco control acts, urban planning for physical activity - which are more relevant for NCDs that have multi-factorial social determinants.
5. Limited applicability in communicable diseases: In CDs, the pathogen (agent) is already present in the environment; the focus is on breaking the chain of transmission (primary prevention). The risk factors for CDs are already established (contaminated water, vectors, carriers), making primordial prevention less applicable.

---

Q2. Life Expectancy is one of the best indicators of a country's level of development - Justify (R.G. Kar MCH)

1. Composite reflection of health status: Life expectancy integrates information on mortality at all ages (infant, child, adult). A high life expectancy means low mortality across all age groups, reflecting good nutrition, healthcare, sanitation, and living conditions.
2. Reflects socioeconomic development: Higher national income, better education, better sanitation, better medical services all contribute to longer life. Thus life expectancy serves as a surrogate measure for overall development.
3. International comparability: It is a standardized measure used by WHO, UNDP Human Development Index (HDI), and World Bank to compare development across nations.
4. Sensitive to policy changes: Improvements in maternal care, child nutrition programs, disease control programs directly raise life expectancy, making it a sensitive policy outcome indicator.
5. Current data (Park): Global life expectancy at birth is approximately 73 years (2019). High-income countries average 80+ years; low-income countries average around 62 years, clearly reflecting the development gradient.
6. Limitations acknowledged: Life expectancy alone does not reflect quality of life, morbidity burden, or disease-free years. Hence supplementary measures like DALY, HALE (Healthy Life Expectancy) are also used.

---

Q3. DALY (Disability Adjusted Life Year) (Jhargram)

• YLL (Years of Life Lost) due to premature mortality
• YLD (Years Lived with Disability) for incident cases of the health condition

• YLL = Number of deaths x Standard life expectancy at age of death
• YLD = Number of incident cases x Disability weight x Average duration of case

1. Measures the total burden of disease in a population
2. Compares burden of different diseases (e.g., TB vs. cardiovascular diseases)
3. Used in cost-effectiveness analysis - "cost per DALY averted"
4. Helps in priority setting in health policy
5. Used in Global Burden of Disease (GBD) studies by WHO/World Bank

---

Q4. Disability Rates (RGKMC)

1. Cause-specific disability rate = (Number of persons disabled due to specific cause / Total population) x 1000
2. Age-specific disability rate = Disabilities in specific age group / Population of that age group x 1000
3. Work-loss rate = Days lost from work due to illness/injury / Number of persons employed x 1000
4. Bed-disability rate = Days spent in bed due to illness/injury / Number of persons in population x 1000

• Impairment - loss/abnormality of psychological, physiological, or anatomical structure
• Disability - restriction/lack of ability to perform an activity in normal manner
• Handicap - disadvantage resulting from disability that limits fulfillment of normal role

---

Q5. Isolation and Quarantine are not synonymous (KPCMCH)

• Separation of infected persons from others during the period of communicability
• Applied to persons who are KNOWN to have a communicable disease
• Example: A cholera patient admitted to an isolation ward
• Duration: Till the person is no longer infectious
• May be strict (complete separation), modified, or partial

• Limitation of freedom of movement of persons/animals who have been exposed to a communicable disease for a period equal to the longest incubation period
• Applied to persons EXPOSED (contacts), not necessarily infected
• May be absolute (complete segregation) or modified (surveillance without segregation)
• Example: Close contacts of COVID-19 kept under quarantine for 14 days

---

Q6. Health is Multi-dimensional - Justify (Murshidabad)

1. Physical dimension: Ability of the body to perform daily tasks without undue fatigue. Includes body size, shape, sensory acuity, physiological fitness (cardiovascular fitness, muscular strength, flexibility).
2. Mental/Psychological dimension: Ability to think clearly and coherently. Includes emotional, intellectual, and behavioral aspects. Absence of mental illness, ability to cope with daily stress.
3. Social dimension: Ability to make and maintain adequate relationships with others. Includes interpersonal skills, community participation, social support networks.
4. Spiritual dimension: Relates to moral/ethical values, life purpose, and meaning. Some define it as adherence to religious beliefs.
5. Emotional dimension: Ability to recognize, accept, and express feelings appropriately. Includes self-acceptance, self-control, capacity to enjoy life.
6. Vocational dimension: Ability to engage in productive and rewarding work.
7. Environmental/Ecological dimension (added later): Ability to live in a healthy physical and social environment.

• A physically fit person suffering from depression or social isolation cannot be called "healthy"
• WHO's positive concept moves beyond merely "absence of disease"
• Dimensions interact with each other: poor mental health leads to poor physical health (e.g., stress causes hypertension)
• Global health programs address all dimensions through Sustainable Development Goals (SDGs)

---

Q7. A Family Plays an Important Role in Health and Disease - Justify (Murshidabad)

1. Disease transmission: Family is the primary unit for transmission of infectious diseases. Spread of tuberculosis, hepatitis A, typhoid within households is well documented.
2. Genetic factors: Hereditary diseases (diabetes, hypertension, familial hypercholesterolemia) cluster within families.
3. Health behavior formation: Dietary habits, exercise patterns, tobacco/alcohol use, hygiene practices are shaped within the family.
4. Emotional support and mental health: Family provides the primary emotional support network. Family conflicts and dysfunction are major risk factors for mental illness, substance abuse, and domestic violence.
5. Child health and development: Mother's health, breastfeeding, immunization compliance, nutritional status - all family-determined factors shape a child's health trajectory.
6. Caregiver role in disease: Family members are primary caregivers in chronic illness (cancer, disabilities). Quality of family support determines outcomes.
7. Socioeconomic health determinants: Family income, educational levels, and social class determine access to nutrition, healthcare, safe housing - all key health determinants.
8. Family life cycle: Vulnerability to specific health problems changes with family life cycle stages (newly married, childbearing, elderly couple).

---

CHAPTER 2: EPIDEMIOLOGY - OUTBREAK INVESTIGATION

---

SCENARIO Q1: Acute Gastroenteritis Outbreak after Community Feast - Purba Medinipur (Tamralipto Govt. MCH)

Part A: Define Epidemic (2 Marks)

• Excess over expected (normal) frequency
• Community/region must be specified
• Time period must be specified
• A single case of a rare disease absent from population may be considered an epidemic

Part B: Steps in Investigation of Epidemic - Citing Gastroenteritis Example (6 Marks)

• Visit the affected village and personally examine a representative sample of cases
• Confirm clinical features of acute gastroenteritis: vomiting, diarrhea, nausea, abdominal cramps
• Collect stool samples, vomit samples, rectal swabs for microbiological examination (to identify organism - Salmonella, V. cholerae, S. aureus, Bacillus cereus, etc.)
• Blood samples for serology if needed
• The epidemiological investigation should not wait for lab results

• Compare current cases with baseline/expected number of AGE cases in the same period in previous years
• In this case: clustering after a single community feast with many cases - this is obviously an epidemic (common source outbreak)
• Apply case definition: a person who attended the feast AND developed 3 or more loose stools with/without vomiting within 72 hours

• Prepare a line listing: name, age, sex, address, date/time of onset, food items consumed, outcome
• Construct a spot map showing geographic distribution of cases in the village
• Draw an epidemic curve (x-axis: time of onset; y-axis: number of cases)
• A sharp, single-peaked curve with short incubation period suggests common-source/point-source epidemic from the feast

• Time: When did cases start? Incubation period from the feast? (helps narrow down causative agent - e.g., 1-6 hrs: S. aureus or B. cereus; 6-24 hrs: Salmonella/C. perfringens; 24-72 hrs: V. cholerae)
• Place: All cases clustered in feast attendees vs. non-attendees? Any cases from other villages?
• Person: Which age groups, sex, specific food items consumed?

• From the data: Likely food-borne common-source outbreak at community feast
• Hypothesis: A specific contaminated food item served at the feast is the vehicle

• Conduct a retrospective cohort study (most appropriate): compare attack rates among those who ate specific food items vs. those who did not
• Calculate Attack Rate for each food item: (Those who ate item X and fell ill / Total who ate item X) x 100
• Calculate Relative Risk for each food item
• The food item with highest attack rate among those who consumed it = suspect vehicle

• Inspect the feast site, food preparation area, water supply used for cooking
• Interview food handlers for symptoms, personal hygiene practices
• Collect food samples (leftover food, water) for culture
• Assess food storage, cooking temperatures, time-temperature abuse

• Treat all cases with ORS, IV fluids if needed
• Safe drinking water and sanitation at feast site
• Report to CMOH/IDSP

• Submit epidemiological report to CMOH, District authorities
• Monitor for new cases
• Evaluate effectiveness of control measures

Part C: Immediate Control Measures While Investigation is in Progress (2 Marks)

1. Treat cases promptly: Establish ORT corners/rehydration centers. Give ORS to all mild cases; IV Ringer's Lactate for severe dehydration cases. Refer severe/complicated cases to PHC/CHC/hospital.
2. Remove/destroy suspected food: Withdraw and destroy any remaining feast food; close the food stalls/preparation areas involved.
3. Safe water supply: Chlorinate water sources; distribute ORS and chlorine tablets; advise boiling of drinking water.
4. Hygiene instructions: Public health education on hand washing, food hygiene to the village community.
5. Notification: Report to BMOH/CMOH under IDSP (Integrated Disease Surveillance Programme). Activate rapid response team.
6. Isolate cases with cholera suspicion if applicable.

---

SCENARIO Q2: 85 Cases Acute Diarrhoeal Disease After Community Feast (Midnapore)

Part 1: Is this Epidemic or Outbreak? (2 Marks)

• 85 cases in a village within 3 days after a community feast = Both an outbreak AND an epidemic
• It is an outbreak because it is geographically confined to the village/feast attendees
• It is epidemic because 85 cases within 3 days is clearly in excess of normal expectancy for AGE in that village
• The temporal clustering (following a single feast = common-source/point-source outbreak) confirms this is a food-borne outbreak

• Excess over expected baseline: Yes (AGE normally would not produce 85 cases in 3 days in a small village)
• Common exposure source: Community feast
• Defined community and time period: Yes

Part 2: Steps in Investigating - Same as above (8 Marks) - Follow steps 1-9 listed above.

Part 3: Epidemiological Study Design to Identify Source (3 Marks)

• Why retrospective cohort? Exposure (specific food items eaten) and disease (AGE) have both already occurred
• All feast attendees form the cohort
• Divide into: exposed (ate specific food item) vs. unexposed (did not eat that item)
• Measure: Attack Rate in exposed vs. not exposed
• Calculate Relative Risk (RR) = Attack rate in exposed / Attack rate in unexposed
• Food item with highest RR is the vehicle

Part 4: Two Immediate Control Measures (2 Marks)

1. ORS distribution and treatment of all affected persons; IV fluids for severe dehydration
2. Withdrawal of suspect food items and chlorination of water supply used for the feast

---

SCENARIO Q3: Acute Watery Diarrhoea - 45 Admitted to PHC, 2 Deaths (Barasat GMC&H)

Step-by-Step Outbreak Investigation (6 Marks) - Same systematic steps as above (Steps 1-9).

Define Attack Rate and Calculate (4 Marks)

• Total village population = 1,500 (assumed all at risk in this village outbreak)
• Number of new cases = 45 (admitted to PHC)
• Attack Rate = (45/1500) x 100 = 3%

Immediate and Long-term Environmental Sanitation Plan (5 Marks)

1. Emergency chlorination of all water sources (wells, hand pumps) - add bleaching powder
2. Distribute safe drinking water/water purification tablets to all households
3. Set up ORT corners and rehydration points at PHC and community level
4. Proper disposal of excreta and vomit (lime powder) to prevent further fecal-oral spread
5. Suspend the community feast and confiscate/destroy remaining food
6. Health education to community on hand washing, safe food

1. Construction of sanitary latrines under SBM (Swachh Bharat Mission) - achieve ODF status
2. Piped water supply from treated source to all households
3. Solid waste management system
4. Food safety training for vendors and cooks
5. Regular bacteriological testing of water supply
6. Health education and WASH programs (Water, Sanitation, Hygiene) in schools and communities
7. Strengthening IDSP surveillance for early detection of future outbreaks

---

SCENARIO Q4: Children with Fever + Jaundice After Village Fair (College of Medicine & Sagore Dutta Hospital) (2+5+3=10)

Most Probable Diagnosis (2 Marks)

• Age group: 5-10 years (school children - most susceptible to Hep A)
• Symptoms: Fever, loss of appetite, nausea, yellowish discoloration of eyes and skin (jaundice) - classic features of Hepatitis A
• Exposure: Fast food stalls (fuchka, velpuri, jhalmuri) at village fair = fecal-oral route transmission via contaminated food/water
• Incubation period: 15-50 days (mean 28 days) - two weeks after fair exposure is consistent
• Hepatitis A is a common-source food/water-borne outbreak in India

Steps of Investigation (5 Marks)

1. Verify diagnosis - clinical examination + serological test: IgM anti-HAV antibody (confirmatory for acute Hep A)
2. Confirm epidemic - compare with baseline Hep A cases in the block
3. Prepare line list of all cases; draw spot map; construct epidemic curve
4. Define case: child 5-10 years, attending fair, onset of jaundice with fever within 50 days of fair
5. Characterize by time, place, person: stall-specific attack rates, type of food consumed
6. Retrospective cohort study: Compare attack rates among those who ate from specific stalls vs. those who did not
7. Environmental investigation: Inspect stalls for food hygiene, water source, handwashing facilities
8. Collect specimens: Stool, serum from cases; food/water samples from stalls for testing

Control Measures (3 Marks) - Immediate:

1. Remove cases from school (exclude till non-infectious)
2. Immediate sanitation at fair grounds; destroy contaminated food; clean water supply
3. Active surveillance for new cases
4. Hepatitis A vaccine (passive: HAV Ig) to close contacts
5. Strict food hygiene enforcement at all food stalls

Measures to Prevent Recurrence:

1. Mandatory food safety training and licensing for all food vendors at fairs
2. Safe water supply and handwashing facilities at all public events
3. Hepatitis A vaccination in school children (under UIP consideration)
4. FSSAI regulation and inspection of food stalls
5. Health education on fecal-oral disease prevention

---

SCENARIO Q5: Dengue Fever - 15-year-old Boy, Kamarpukur BPHC (PC Sen) (4+6+5=15)

Intern's Steps to Diagnose and Manage (4 Marks):

• Clinical features: Fever, headache, retro-orbital pain, rash, bleeding = Classic dengue
• Tourniquet test (Rumpel-Leede test): Apply BP cuff at midpoint of systolic and diastolic BP for 5 min; >10-20 petechiae per sq inch = positive
• Investigations: CBC (thrombocytopenia - platelets <1 lakh, HCT rise >20% = dengue), NS1 antigen (positive day 1-5), IgM/IgG ELISA, SGOT/SGPT

• Shift to dengue ward with mosquito net
• IV fluids (Ringer's Lactate) for shock (BP 90/60 = compensated shock)
• Monitor pulse, BP, urine output hourly
• Platelet transfusion if platelets <20,000 or active bleeding
• Avoid NSAIDs/aspirin (increase bleeding risk)
• Inform CMOH under NVBDCP (National Vector Borne Disease Control Programme)

Steps taken by BMOH (6+5 Marks):

1. Visit the locality; conduct rapid case survey; prepare line listing of all fever cases
2. Active case search: House-to-house survey for fever cases; collect blood samples (rapid dengue test) from suspected cases
3. Entomological survey: Larval survey (Aedes aegypti breeding sites) - check for stagnant water in containers, tires, flower pots, overhead tanks; calculate Larval/House Index, Breteau Index
4. If indices exceed threshold: Spray anti-larval measures (temephos/Bacillus thuringiensis israelensis) in breeding sites
5. Anti-adult measures: Indoor Residual Spraying (IRS), Space spraying (fogging with pyrethroid) in affected area
6. Notification to CMOH; report under IDSP
7. Health education to community: source reduction (remove stagnant water, use mosquito nets, repellents)
8. School-level education campaign in affected locality

---

SCENARIO Q6: Outbreak of Diarrhoea Under-5 Children, Purba Bardhaman (Burdwan Medical College) (1+1+8=10)

Define Outbreak (1 Mark)

How Outbreak Differs from Epidemic (1 Mark)

Investigation and Management as BMOH (8 Marks):

1. Verify diagnosis: Examine cases; stool microscopy/culture
2. Confirm outbreak: Compare with expected baseline diarrhoea cases in under-5 in the block
3. Case definition: Under-5 child with 3+ loose stools/day with/without vomiting
4. Line listing: Name, age, address, onset date, water source, food, breastfeeding status, vaccination status
5. Epidemic curve: Determine if common-source or propagated
6. Spot map: Clustering by specific area, water source, feeding pattern
7. Characterize by Person: Age (neonates vs. 1-5 yr), sex, feeding (breastfed vs. not), nutritional status, vaccination (rotavirus)
8. Hypothesis: Common water source contamination / contaminated supplementary food / poor hygiene
9. Case-control study: Cases = sick children; controls = non-sick children of same age; compare water source, hygiene, food
10. Environmental: Water testing, sanitation inspection, food handler testing

• Set up ORT corners at AWC (Anganwadi Centres) and subcentres
• ORS + zinc supplementation for all children as per guidelines
• Refer severe cases to CHC/hospital
• Chlorinate water sources
• Health education to mothers on ORS preparation, handwashing, safe weaning foods
• Notify ICDS supervisors and AWW (Anganwadi Worker) for active community response
• Rotavirus vaccination reinforcement
• Report under IDSP; activate RRT (Rapid Response Team)

---

SCENARIO Q7: 250 Cases Acute Watery Diarrhoea in 2 Days, 5 Deaths (IQ City Medical College) (1+6+3+5=15)

Define Outbreak (1 Mark) - Same as above.

Steps to Investigate (6 Marks) - Same systematic approach as outlined above.

Draw and Interpret Epidemic Curve (3 Marks)

• X-axis: Time (hours/days from first case)
• Y-axis: Number of new cases per time unit

• A sharp, single spike (bell-shaped, narrow peak within 1-2 days) = Point-source epidemic (single contaminated food item at feast) - consistent with 250 cases in 2 days
• If cases continue to appear in waves after the initial peak = Propagated epidemic (person-to-person spread)
• The peak of the curve minus the minimum incubation period gives the time of exposure (the feast)
• Tail of the curve represents secondary cases from person-to-person spread

Control Measures (5 Marks)

1. Establish emergency rehydration centers at PHC/CHC; deploy ORS, IV fluids
2. Withdraw and destroy suspect food; close feast preparation site
3. Emergency chlorination of all water sources
4. Collect food/water/stool samples before destroying evidence
5. Notification to CMOH; activate IDSP rapid response team

1. Sanitary latrine construction (SBM); achieve ODF
2. Piped drinking water with treatment
3. Food safety training and enforcement for public caterers
4. Community hygiene education - WASH program
5. School health programs on hand hygiene

---

CHAPTER 2: EPIDEMIOLOGICAL STUDY DESIGNS

---

Q: Prevalence of Obesity Among Medical Students - 3 months (Barasat GMC&H) (2+13=15)

Study Type (2 Marks)

• Objective is to find prevalence (not incidence) of obesity
• Time period is 3 months (short) - not enough for cohort study
• No follow-up needed - one-time measurement
• Suitable for describing health status of defined population at a point in time

Steps of Cross-sectional Study (13 Marks)

1. Define study population: All medical students of the institution (Barasat GMC&H) currently enrolled
2. Sample size calculation: Using formula n = Z²PQ/d²
   • P = expected prevalence of obesity in medical students (estimate from literature ~15-20%)
   • Z = 1.96 (95% confidence), d = desired precision (5%)
   • Calculate sample size accordingly
3. Sampling technique: Stratified random sampling - stratify by year of MBBS (1st to final year) to ensure all batches are represented
4. Case definition of obesity: BMI ≥ 30 kg/m² (WHO definition); or use Asian cutoffs (BMI ≥ 25 = overweight, ≥ 27.5 = obese)
5. Data collection tool: Structured questionnaire covering:
   • Demographic data (age, sex, year)
   • Dietary history (24-hour dietary recall, food frequency questionnaire)
   • Physical activity (IPAQ questionnaire)
   • Anthropometry: Weight (calibrated scale), Height (stadiometer), Waist circumference, BMI calculation
   • Sedentary behavior (screen time, study hours)
6. Ethical clearance: Obtain from Institutional Ethics Committee; written informed consent from each student
7. Pilot study: 10% of sample size to pre-test the tool
8. Data collection: Trained data collectors measure weight, height, calculate BMI; administer questionnaire
9. Data entry and cleaning: Enter data in Excel/Epi Info/SPSS; check for outliers
10. Analysis:
    • Descriptive: Prevalence of obesity = (Number with BMI ≥ 30 / Total students surveyed) x 100
    • Chi-square test: Association between obesity and gender, year of study, dietary habits
    • Logistic regression: Identify predictors of obesity
11. Report writing and dissemination

• Quick, inexpensive, feasible within 3 months
• No loss to follow-up
• Can study multiple variables simultaneously
• Gives prevalence data

• Cannot establish causality (temporal relationship)
• Susceptible to selection bias and prevalence-incidence bias
• Cross-sectional data may not represent future burden

---

Q: Cohort Study - Study Design for Radiation Workers in Nuclear Plant over 5 Years (JNM Kalyani) (2+8+5=15)

Ideal Study Design (2 Marks)

• Exposure (radiation) is already defined and measurable at start
• Disease (radiation-induced illness) may develop over years - 5-year follow-up is appropriate
• Can calculate Relative Risk, Incidence Rate, Attributable Risk
• Temporal sequence established (exposure precedes disease)

Steps in Conducting Cohort Study (8 Marks)

1. Define study population (Cohort):
   • Exposed cohort: Workers at the nuclear plant with documented radiation exposure
   • Unexposed cohort: Workers in the same plant in administrative/non-radiation areas OR workers in other industries
2. Eligibility criteria:
   • Inclusion: All workers at nuclear plant, age 18-60 years, willing to participate
   • Exclusion: Pre-existing radiation-related illness, prior cancer diagnosis
3. Baseline assessment:
   • Measure radiation exposure level (dosimeter readings - millisieverts)
   • Classify into exposure levels: High (>20 mSv/yr), Medium (10-20), Low (<10)
   • Baseline health status: Complete physical exam, CBC, LFT, RFT, chest X-ray
   • Demographic data: Age, sex, occupation, smoking, other exposures
4. Follow-up:
   • Annual health checkups over 5 years
   • Monitor for outcomes: Leukemia, thyroid cancer, cataracts, infertility, other cancers
   • Measure radiation dose continuously (personal dosimeters)
   • Track loss to follow-up; minimize attrition
5. Outcome measurement:
   • Define outcome precisely: e.g., newly diagnosed leukemia (ICD codes)
   • Standardized diagnostic criteria for each outcome
6. Analysis:
   • Calculate Incidence Rate in exposed and unexposed groups
   • Relative Risk (RR) = Incidence in exposed / Incidence in unexposed
   • Attributable Risk (AR) = Incidence in exposed - Incidence in unexposed
   • Population Attributable Risk (PAR)
   • Control for confounders: Age, smoking (stratification/regression)
7. Ethical considerations:
   • Informed consent from all participants
   • IEC approval
   • Provide protective equipment; reduce exposure where possible (ethical obligation)

Disadvantages of Cohort Study (5 Marks)

1. Long duration and expensive: 5-year follow-up requires sustained funding, large team
2. Loss to follow-up: Workers may resign, relocate, die from unrelated causes - threatens internal validity
3. Not suitable for rare diseases: If radiation-induced cancer is rare, need very large sample sizes
4. Exposure misclassification: Dosimeter readings may not perfectly capture actual biological dose
5. Healthy worker effect bias: Workers selected for nuclear plant are healthier than general population - may underestimate risk
6. Changes over time: Radiation protection standards, diagnostic technology may change during 5-year period
7. Multiple exposures: Workers may have other occupational exposures (chemicals) that confound results

---

Q: Case-Control Study - Obesity and Osteoarthritis of Knee (PC Sen) (8+4+3=15)

Design of Case-Control Study (8 Marks)

1. Selection of Cases:
   • Cases: Newly diagnosed OA knee patients (confirmed by X-ray - Kellgren-Lawrence Grade ≥ 2), aged 35-65 years, attending orthopedic OPD of a hospital
   • Use incident cases (newly diagnosed), not prevalent cases
   • Apply inclusion/exclusion criteria: Exclude secondary OA (trauma, RA, gout)
2. Selection of Controls:
   • Controls: Persons aged 35-65 years WITHOUT OA knee, attending same hospital (other OPDs) or community-based
   • Match controls to cases on age (±5 years), sex, and socioeconomic status (confounders)
   • Ratio: 1 case : 1 or 2 controls (2 controls increase power)
3. Matching:
   • Individual matching: Each case matched with a control of same age and sex
   • This controls for potential confounding by age and sex
4. Exposure measurement:
   • BMI calculation: Weight (kg)/Height² (m²)
   • Obesity defined as BMI ≥ 30 kg/m²
   • Also collect data on duration of obesity, weight history
   • Recall period: Current BMI + BMI at age 30 (past exposure)
5. Data collection: Structured questionnaire + physical examination for BMI; blinded assessor for outcome verification
6. Analysis:
   • Construct 2x2 table (Exposed/Not Exposed vs. Cases/Controls)
   • Calculate Odds Ratio (OR) = ad/bc
   • OR >1 with 95% CI not crossing 1 = significant association
   • Logistic regression for multivariate analysis controlling confounders
7. Sample size: Based on expected OR (say 2.5), prevalence of obesity in controls (~20%), power 80%, alpha 0.05

Advantages of Case-Control Study (4 Marks)

1. Suitable for rare diseases: OA is not rare, but case-control suits rare diseases well
2. Relatively quick and inexpensive compared to cohort study
3. Efficient for studying multiple exposures: Can study obesity, physical activity, diet, occupation simultaneously as risk factors for OA
4. No follow-up needed: Both exposure and disease have already occurred
5. Less loss to follow-up (cross-sectional data collection)
6. Provides Odds Ratio as measure of association

Disadvantages of Case-Control Study (4 Marks)

1. Recall bias: Cases (OA patients) may better recall past obesity than controls - overestimates OR
2. Selection bias: Hospital-based controls may not represent general population
3. Cannot calculate incidence or RR - only Odds Ratio (approximation of RR when disease is rare)
4. Temporality difficult to establish: Hard to know if obesity preceded OA
5. One outcome at a time: Can only study one disease (OA knee) per study

Biases in Case-Control Study (3 Marks)

1. Selection Bias:
   • Berkson's bias (hospital admission bias): Both cases and controls from hospital may not represent community
   • Neyman's bias (prevalence-incidence bias): Using prevalent rather than incident cases
2. Information/Recall Bias:
   • Differential recall: Cases (with OA) recall past obesity more vividly than controls
   • Interviewer bias: Interviewer probes more for obesity history in cases
3. Confounding:
   • Age, sex, physical activity level, occupation (standing/kneeling work) are confounders for OA
   • Controlled by matching and multivariate analysis

---

Q: Compare Two Drugs for Hypertension - Study Design (IQ City Medical College) (1+6+3=10)

Appropriate Study Design (1 Mark)

Steps in Conducting RCT (6 Marks)

1. Define hypothesis: Drug A is more effective than Drug B in reducing SBP by ≥5 mmHg in hypertensive patients over 3 months
2. Define eligibility criteria:
   • Inclusion: Adults 30-65 years, diagnosed hypertension (SBP ≥140 or DBP ≥90 mmHg), willing to participate
   • Exclusion: Secondary hypertension, pregnancy, severe renal/hepatic disease, already on >2 antihypertensives
3. Sample size calculation: Based on expected difference in mean BP reduction, standard deviation, alpha 0.05, power 80%
4. Randomization:
   • Simple randomization: Random number table or computer-generated sequence
   • Concealment of allocation: Sealed opaque envelopes or central allocation - ensures concealment from recruiter
   • Purpose: To ensure comparable groups at baseline; eliminates selection bias
5. Blinding:
   • Double blind: Patient does not know which drug they receive; physician/assessor does not know - eliminates performance bias and detection bias
   • Identical-looking capsules (placebo-matching)
6. Intervention:
   • Group A: Drug A (e.g., Amlodipine 5 mg/day)
   • Group B: Drug B (e.g., Telmisartan 40 mg/day)
   • Duration: 3 months follow-up
7. Outcome measurement: BP measured at 4, 8, 12 weeks; adverse events recorded; compliance assessed (pill count)
8. Analysis: Intention-to-treat analysis (analyze all randomized, even those who dropped out) to prevent overestimation of effect

Biases and Their Control (3 Marks)

---

Q: Define Epidemiology, Classify Studies, Steps of Cohort Study, Bias (MCK) (2+5+5+3=15)

Define Epidemiology (2 Marks)

• Distribution: Who, when, where (person, time, place)
• Determinants: Why and how (causes, risk factors)
• Health-related states: Disease, disability, death, health-related behavior
• Specified populations: Defined community, not individuals
• Application: Public health action

Classification of Epidemiological Studies (5 Marks)

EPIDEMIOLOGICAL STUDIES
├── OBSERVATIONAL
│   ├── DESCRIPTIVE
│   │   ├── Case reports / Case series
│   │   ├── Ecological (Correlational) studies
│   │   └── Cross-sectional (Prevalence) studies
│   └── ANALYTICAL
│       ├── Case-Control study
│       └── Cohort study (Prospective/Retrospective)
└── EXPERIMENTAL (INTERVENTIONAL)
    ├── Randomized Controlled Trial (RCT)
    ├── Community Trial (Field Trial)
    └── Natural Experiment

Steps of Cohort Study (5 Marks)

1. Select exposed group (e.g., smokers) and unexposed group (non-smokers) - free of disease at start
2. Match groups on confounders (age, sex, socioeconomic status)
3. Baseline assessment: Confirm disease-free status; measure exposure level; collect demographic data
4. Follow-up over defined period (years): Monitor for development of disease; minimize loss to follow-up
5. Outcome ascertainment: Standardized, blinded diagnosis of outcomes
6. Analysis: Calculate and compare incidence rates; Relative Risk = Incidence in exposed / Incidence in unexposed; Attributable Risk

Bias in Cohort Study (3 Marks)

1. Selection bias: Healthy worker effect (exposed workers healthier than unexposed general population - underestimates risk); Volunteer bias
2. Information bias: Exposure misclassification (dose measurement error); Differential loss to follow-up (those who develop disease may drop out - attrition bias)
3. Confounding: Factors associated with both exposure and outcome (e.g., smoking as confounder for alcohol-disease association)
4. Temporal bias: Latency period may exceed follow-up duration; disease not yet manifested at end of study

---

Q: OCP and Breast Cancer - Causal Association Study (ESI Joka) (1+2+6+3+3=15)

Study Type (1 Mark)

Why Case-Control? (2 Marks)

1. Breast cancer is relatively rare - case-control more efficient than cohort (cohort would need enormous sample for rare outcome)
2. Long latency period between OCP use and breast cancer development - a prospective cohort would take decades
3. OCP use is a past exposure - can be recalled by cases and controls

Steps of Case-Control Study (6 Marks) - Follow same steps as OA/obesity case-control above, adapted for this scenario.

Advantages (3 Marks)

1. Suitable for rare diseases (breast cancer)
2. Can study multiple risk factors simultaneously (OCP dose, duration, age at first use, family history)
3. Relatively quick and cheap
4. No follow-up needed

Disadvantages (3 Marks)

1. Recall bias: Breast cancer patients may selectively remember OCP use
2. Cannot calculate incidence or RR directly
3. Temporality difficult to establish (did OCP use truly precede cancer?)
4. Selection bias in choosing controls

---

Q: Causal Association Criteria - Framingham Study (KPC Medical College) (1+5+4+5=15)

Type of Study (1 Mark)

Steps (5 Marks) - Same as cohort study steps above.

Advantages and Disadvantages (4 Marks) - Same as cohort study above.

Criteria for Judging Causal Association - Bradford Hill's Criteria (5 Marks)

1. Strength of association: Stronger the association (higher RR/OR), more likely it is causal. RR >2 is strong.
2. Consistency: Association observed in different studies, populations, times, and places.
3. Specificity: One cause producing one specific effect (less strict criterion today).
4. Temporality: Cause must precede effect (the only essential criterion). Exposure before disease onset.
5. Biological gradient (Dose-response): More exposure = more disease (e.g., more cigarettes = more lung cancer).
6. Plausibility: Biological mechanism exists or is plausible.
7. Coherence: Association consistent with known biology/natural history of disease.
8. Experiment: Removing the cause reduces the disease (experimental evidence).
9. Analogy: Similar associations exist for related causes/effects.

---

Q: Air Pollution and Bronchial Asthma in School Children (Sarat Chandra Chattopadhyay GMC) (3+6+3+3=15)

Most Appropriate Study Design (3 Marks)

• Exposure (air pollution level) can be measured and categorized at baseline
• Outcome (asthma incidence) not yet occurred in all children at study start
• Can establish temporality: Pollution exposure → Asthma
• Can measure dose-response relationship (pollution level vs. asthma risk)
• Better suited than cross-sectional (cannot establish temporal sequence)

Methodology (6 Marks) - Same cohort study steps.

Strengths of Cohort in Establishing Temporal and Causal Relationship (3 Marks)

1. Temporal sequence established: Exposure measured before outcome occurs - confirms that pollution came before asthma
2. Incidence rate calculable: Can directly measure RR (not just OR)
3. Dose-response assessable: Pollution levels at different schools measured; can correlate with asthma incidence (supports causality per Hill's criteria)
4. Multiple outcomes measurable: Can also study rhinitis, COPD, CVD effects of pollution simultaneously

Sources of Bias (3 Marks)

1. Selection bias: Schools selected may not represent all urban schools; healthier children more likely to be enrolled
2. Information bias: Air pollution monitoring may not accurately reflect personal exposure; asthma diagnosis may vary between clinicians (differential misclassification)
3. Confounding: Indoor air pollution, parental smoking, family history of atopy, socioeconomic status - all confounders for asthma
4. Loss to follow-up: Children change schools, move cities over the study period

---

Q: Obesity and Hypertension - Cohort Study - 6000 Adults (Deben Mahata GMC&H) (1+6+2+2+4=15)

Study Design (1 Mark)

Steps (6 Marks) - See cohort study steps above.

Advantages (2 Marks)

• Establishes temporality (obesity before hypertension)
• Calculates incidence and Relative Risk directly

Disadvantages (2 Marks)

• Long duration, expensive; Loss to follow-up over 15 years

Analysis of Findings (4 Marks)

• Obese group: 2000 persons, 200 developed hypertension
• Non-obese group: 4000 persons, 100 developed hypertension

---

Q: Time Trends in Disease Occurrence (R.G. Kar MCH) (12+3=15)

Types of Time Trends (12 Marks)

• Example: Declining TB mortality in England even before antibiotics (due to improved nutrition/living conditions)
• Rising prevalence of diabetes and obesity globally
• Declining polio cases following OPV introduction

• Seasonal trends: Diseases that peak at particular seasons each year
  • Malaria: Peaks post-monsoon (Aug-Nov) due to Anopheles breeding
  • Acute respiratory infections: Peak in winter
  • Cholera: Peak in summer and post-monsoon
• Cyclic trends: Regular but less frequent cycles
  • Influenza pandemics: ~10-40 year cycles
  • Measles epidemics: 2-3 year cycles before vaccination

• Epidemic outbreaks (e.g., cholera outbreak after flood)
• Point-source epidemics (rapid rise and fall)

• Abrupt rise in cases following single exposure (food poisoning, contamination)

Factors to Keep in Mind While Interpreting Time Trends (3 Marks)

1. Artifacts:
   • Changes in diagnostic criteria: Broadening of ICD codes increases apparent incidence
   • Improved diagnostic tools: Better diagnostics detect previously missed cases (e.g., improved cancer screening)
   • Changes in reporting/surveillance: Better notification increases recorded incidence
2. Real changes:
   • Changes in agent virulence
   • Changes in host susceptibility (herd immunity, nutrition)
   • Changes in environmental exposures
3. Population changes: Age distribution of population changes; age-standardization needed for fair comparison
4. Regression to mean: Extreme values tend to return to average over time

---

IMMUNIZATION

---

Q: National Immunization Schedule for Infants + Eradication of Poliomyelitis (KPCMCH)

National Immunization Schedule for Infants (Park's Textbook - UIP Schedule)

Hepatitis B at Birth - Justify (Sanaka, PC Sen):

1. Prevention of perinatal transmission: HBV can be transmitted from HBsAg-positive mother to neonate at birth (vertical transmission). Without immunization, 70-90% of perinatally infected infants become chronic carriers.
2. Window of protection: Birth dose given within 24 hours of birth provides protection before the virus can establish infection. Combined with HBIG (if mother is HBeAg positive), efficacy >95%.
3. Chronic carrier prevention: HBV acquired in infancy has 90% risk of becoming chronic (vs. 5-10% in adults). Birth dose prevents lifetime carrier state.
4. HBV leads to cirrhosis and hepatocellular carcinoma in chronic carriers - birth dose prevents this serious long-term outcome.

OPV Given at Birth Despite Subsequent Doses - Justify (Tamralipto):

1. Birth dose provides early mucosal immunity: OPV at birth stimulates gut mucosal IgA production early, before polio exposure risk
2. Maternal antibody interference reduced: At birth, maternal antibody levels vary; the zero dose primes the gut before maternal antibodies wane
3. Additional dose increases seroconversion rates: An extra dose improves cumulative seroconversion for all 3 poliovirus serotypes
4. Polio eradication strategy: In high-risk areas with potential wild poliovirus circulation, maximum number of OPV doses is the strategy
5. Zero dose does not replace subsequent doses - it primes; the primary immunization series at 6, 10, 14 weeks completes protection

Current Strategies for Eradication of Poliomyelitis (Park):

1. Routine Immunization: Universal Immunization Programme - OPV 0,1,2,3 + booster; IPV added to schedule
2. Pulse Immunization (NIDs): National Immunization Days - all children under 5 years receive OPV regardless of prior immunization status; conducted twice yearly
3. Sub-National Immunization Days (SNIDs): Targeted in high-risk areas
4. Intensive Pulse Immunization: In outbreak areas - rounds of OPV every 4-6 weeks
5. Mop-up operations: House-to-house OPV administration in area of reported wild polio case
6. Acute Flaccid Paralysis (AFP) Surveillance: Every AFP case in <15 year child investigated within 48 hours; stool samples sent for poliovirus isolation
7. IPV in schedule: Inactivated Polio Vaccine added to routine schedule for additional protection against Vaccine-Derived Poliovirus (VDPV)
8. India declared polio-free on March 27, 2014 - no wild poliovirus since January 2011

---

Q: AEFI - Adverse Events Following Immunization (JMN, Malda)

Most Probable Diagnosis in First Child (2 Marks)

• Onset within 30 minutes (anaphylaxis occurs within minutes of exposure)
• Features: Difficulty breathing (bronchospasm), generalized rash (urticaria), loss of consciousness (hypotension/shock)
• This is a serious AEFI requiring immediate emergency treatment

Classification of AEFI (Park) (5 Marks for Malda; 3 Marks for JMN)

1. Vaccine product-related reaction: Caused by inherent properties of the vaccine (e.g., fever after whole-cell DPT, local redness after BCG)
2. Vaccine quality defect-related reaction: Caused by defects in manufacturing (e.g., inadequate inactivation of toxin)
3. Immunization error-related reaction (Programmatic error): Due to errors in vaccine preparation, handling, or administration:
   • Wrong diluent used
   • Wrong dose, wrong site, wrong route
   • Non-sterile technique (abscess at injection site)
   • Vaccine not reconstituted properly
   • Vaccine stored incorrectly (cold chain failure)
4. Immunization anxiety-related reaction: Anxiety about immunization:
   • Vasovagal syncope (fainting) during/after injection
   • Hyperventilation
   • These are NOT caused by the vaccine itself
5. Coincidental events: Would have occurred anyway regardless of vaccination; temporal coincidence only

• Serious AEFI: Results in death, requires hospitalization, or causes permanent disability
• Severe AEFI: Severe in intensity (high fever, persistent crying, extensive local reaction) but not necessarily serious
• Non-serious/Minor: Fever, local redness, soreness - expected reactions

Investigation of AEFI at Field Level (6 Marks)

1. Immediate action: Treat anaphylaxis with Adrenaline (Epinephrine) 1:1000, 0.01 mg/kg IM into anterolateral thigh; supplemental oxygen; call ambulance; refer to hospital
2. Report: Fill AEFI reporting form; report to BMOH within 24 hours (serious AEFI = immediate telephonic report)
3. Investigate: Visit session site; inspect remaining vaccine vials, diluents, syringes; review cold chain records; interview vaccinator
4. Collect: Remaining vaccine vials and diluents from the same batch; blood sample from affected child (if possible); send to state vaccine laboratory
5. Case-line list: All children vaccinated in same session - follow up for next 7-14 days for delayed reactions
6. AEFI Committee review at district/state level to assess causality

Preventive Measures for Future (4 Marks)

1. Observation period: Every vaccine recipient should be observed for at least 30 minutes post-vaccination at session site
2. Emergency kit: Adrenaline, antihistamines, IV fluids, oxygen must be available at every vaccination session
3. Trained staff: Vaccinator must be trained to recognize and manage anaphylaxis
4. Screening: Ask about previous allergic reactions before vaccination
5. Proper cold chain: Maintain 2-8°C; avoid freezing (especially DPT, DT, TT, Hepatitis B - freeze-sensitive)
6. Proper reconstitution: Follow instructions exactly; use only specified diluent; discard open vials after session

Types of Reactions Following Immunization (3 Marks)

1. Local reactions: Pain, redness, swelling at injection site (most common, usually mild)
2. Systemic reactions: Fever, malaise, myalgia - within 12-24 hours
3. Allergic reactions: Urticaria, angioedema (delayed), anaphylaxis (immediate) - IgE mediated
4. Neurological reactions: Febrile convulsions (rare, after DPT), encephalopathy (rare)
5. Specific vaccine reactions: BCG - local ulcer, regional lymphadenopathy; Measles vaccine - mild rash on day 7-10; OPV - Vaccine-Associated Paralytic Poliomyelitis (VAPP) 1:750,000 first doses; DPT - persistent inconsolable crying >3 hours, hypotonic-hyporesponsive episode (HHE)

---

Q: Immunization Drop-outs and Left-outs - Meaning, Reasons, Measures (Jhargram)

Definitions

• Example: A child received BCG and OPV at birth but never came back for pentavalent doses at 6 weeks.

• They are "left out" of the immunization program entirely.

Reasons for Drop-outs and Left-outs

1. Inadequate health worker motivation and performance
2. Irregular cold chain supply; vaccine stock-outs at subcentres
3. Vaccination sessions not held regularly; health worker absenteeism
4. Poor outreach to remote/tribal/slum areas
5. Poor community mobilization and IEC activities

1. Poor awareness about immunization benefits and schedule
2. Misconceptions and rumors about vaccine safety
3. Missed opportunities (child sick on vaccination day; health worker didn't vaccinate due to minor illness)
4. Lack of time due to agricultural work; distance to health facility
5. Cultural and religious objections to vaccination
6. Migratory populations not captured in routine schedule

Measures to Improve the Situation (Health Administrator)

1. Strengthen outreach: Conduct regular outreach/fixed vaccination sessions in all areas; conduct special sessions for missed areas
2. Tracking system: Maintain due list of children; ANM/ASHA to follow up defaulters at home visits
3. ASHA mobilization: ASHA workers to mobilize dropouts; provide incentives for bringing children for vaccination
4. Cold chain maintenance: Ensure uninterrupted cold chain at all levels
5. IEC/BCC activities: Regular community meetings, school-based education, radio/TV campaigns about importance of completing immunization
6. Missed opportunity reduction: Vaccinate all eligible children at every health contact regardless of reason for visit
7. District microplanning: Create updated village-level registers; calculate and track coverage rates monthly
8. Social mobilization: Involve PRIs, community leaders, religious leaders to promote immunization
9. Nikshay Poshan Yojana / ADIP approach: Incentivize completion of schedule

---

Q: Electronic Waste Industry and Chronic Kidney Disease - Study Design (RGKMC) (5+4+1=10)

Study Design (5 Marks)

1. Define exposed cohort: Workers at e-waste recycling units handling heavy metals (lead, cadmium, mercury, chromium)
2. Define unexposed cohort: Workers in other industries in same area (administrative staff, non-exposed workers) or community controls
3. Baseline assessment: Blood and urine tests for heavy metal levels (blood lead, urinary cadmium); eGFR, serum creatinine, urine ACR to rule out pre-existing CKD
4. Exposure measurement: Type of work (manual dismantling, burning, acid stripping), duration, hours/day; measure air/blood metal levels
5. Follow-up: Annual eGFR measurement; monitor for CKD development (eGFR <60 ml/min/1.73m² for >3 months)
6. Analysis: Incidence of CKD in exposed vs. unexposed; RR calculation

Sampling Techniques (4 Marks)

1. Simple Random Sampling: Each person in the sampling frame has equal probability of selection; requires complete sampling frame (list of all e-waste workers). Use random number table/computer.
2. Systematic Random Sampling: Select every kth person from list. Sampling interval k = N/n (population/required sample). Easier than SRS for large lists.
3. Stratified Random Sampling: Divide population into strata (e.g., by type of work: manual dismantling vs. acid workers vs. burning workers); select random sample from each stratum. Ensures representation of all exposure types.
4. Cluster Sampling: Divide into clusters (e.g., different e-waste units/factories); randomly select clusters; study all workers in selected clusters. Practical when workers are in multiple scattered units.
5. Multistage Sampling: Combination - first select clusters (units), then systematically sample within clusters.

Suitable Technique for This Study (1 Mark)

---

SHORT NOTES & EXPLANATIONS

---

Bias and Confounding are not Synonymous (CNMC)

• Types: Selection bias, information/measurement bias, reporting bias
• Bias is introduced by the researcher or the study process
• Example: Recall bias (cases recall past exposure better than controls)

• A confounder is: (1) associated with the exposure, (2) independently associated with the outcome, (3) not on the causal pathway
• Example: Age confounds the relationship between alcohol and CVD (older people drink more AND have more CVD)
• Confounding can be controlled by: Restriction, Matching, Stratification, Multivariate analysis

---

Sentinel Surveillance - Useful for Early Outbreak Detection (MCK)

• Not designed to capture all cases but to detect trends
• Selected sites are strategically located (high-risk areas, high patient volume)
• Uses a network of sentinel sites (e.g., sentinel hospitals for influenza surveillance in India)

1. Speed: Sentinel sites report rapidly (weekly); faster than routine passive surveillance
2. Sensitivity: Sites selected in high-risk areas where cases are most likely to appear first
3. Quality of data: Since limited sites participate, data quality and completeness are better
4. Burden-proportionate coverage: Can indicate trends even from partial coverage
5. Cost-effective: Not all facilities needed; selected strategic sites sufficient
6. Examples: IDSP uses sentinel surveillance for influenza-like illness (ILI) and severe acute respiratory illness (SARI); dengue sentinel sites in India

---

Cohort Study - Gold Standard for Temporal Association but Inappropriate for Rare Disease (College of Medicine & Sagore Dutta)

• Exposure is measured at baseline before disease onset
• Follow-up over time shows who develops disease
• Temporal sequence: Exposure → Disease is clearly established
• Calculates Incidence Rate and Relative Risk directly
• Hence "gold standard" for temporal and causal association

• If disease incidence is very low (e.g., 1 per 100,000/year), need an enormous sample size (millions) to get enough cases
• Long follow-up needed (years/decades) - expensive, impractical
• High loss to follow-up with very long duration
• Example: To study radiation exposure and mesothelioma (rare) - a cohort study would need thousands of workers followed for 20+ years; a case-control study (finding existing mesothelioma cases and comparing past radiation history with controls) is far more efficient

---

Relative Risk (RR) Calculation - Silicosis Study (Diamond Harbour GMC&H)

• Incidence in Exposed = 120/800 = 0.15 (15%)
• Incidence in Not Exposed = 30/1200 = 0.025 (2.5%)
• RR = 0.15/0.025 = 6.0

---

Randomization and Blinding are Not Used for the Same Purpose in Clinical Trial (Deben Mahata GMC&H)

• Purpose: To ensure comparable groups at baseline by equally distributing both known AND unknown confounders between treatment arms
• Eliminates selection bias at allocation
• Each participant has equal (or known) probability of being allocated to any group
• Does not involve any masking - participants/investigators may know group allocation
• Example: Random allocation to Drug A vs. Drug B group

• Purpose: To prevent performance bias and detection bias after group allocation
• Keeps participants and/or assessors unaware of which treatment is being given
• Single blind: Patient doesn't know; Double blind: Patient AND assessor don't know; Triple blind: Patient, assessor, AND data analyst don't know
• Does not affect group comparability - randomization already achieved that
• Example: Identical-looking capsules so patient can't tell which drug they're taking

---

RR and AR (Attributable Risk) are Not Synonymous (Midnapore)

• RR = Incidence in exposed / Incidence in unexposed
• Measures the strength of association between exposure and disease
• Used to assess whether causal association exists
• Useful for etiological research
• Example: RR = 4 means exposed are 4 times more likely to get disease

• AR = Incidence in exposed - Incidence in unexposed
• Measures the excess risk of disease due to the specific exposure
• Indicates how many cases can be prevented by eliminating the exposure
• Used for public health action - prioritizing interventions
• Example: AR = 7.5% means 7.5% of cases in exposed are due to the specific exposure

---

Incidence Preferred over Prevalence in Studying Disease Causation (JNM Kalyani)

1. Prevalence reflects both incidence AND duration: A high prevalence disease may be due to high incidence OR long duration (good survival). This makes it impossible to separate "cause of new disease onset" from "factors affecting survival."
2. Incidence = new cases only: Incidence measures the rate of developing new disease in a previously disease-free population. This more accurately represents the risk of getting the disease from a given exposure.
3. Temporal clarity: Incidence studies can establish that exposure occurred before disease onset, supporting causality. Prevalence studies measure point-in-time status, making temporal sequence unclear.
4. Example: HIV prevalence is affected by both new infections AND antiretroviral treatment (extending survival). HIV incidence accurately reflects transmission rates and is preferred for studying risk factors.
5. Confounding by disease duration: Long-duration diseases inflate prevalence. Mild (long-lasting) disease increases prevalence disproportionately.

---

Open Vial Policy (ICARE)

1. The vial has not expired
2. Vaccines are stored under appropriate cold chain conditions (2-8°C)
3. The vial septum has not been submerged in water
4. Aseptic technique has been used

1. Reduces vaccine wastage (significant cost saving)
2. Maintains vaccine availability for subsequent sessions
3. Multi-dose vials contain preservatives (thiomersal) that maintain sterility

---

HPV Vaccination for Prevention of Cervical Cancer (Midnapore, CNMC, Santiniketan, Burdwan) (5 Marks)

• Cervical cancer is the 2nd most common cancer in Indian women (after breast cancer)

• 99% of cervical cancers are caused by HPV (types 16 and 18 responsible for 70% of cases)

• HPV is sexually transmitted

1. Cervarix (bivalent): Protects against HPV 16 & 18
2. Gardasil (quadrivalent): Protects against HPV 6, 11, 16, 18 (also prevents genital warts)
3. Gardasil-9 (nonavalent): Protects against HPV 6, 11, 16, 18, 31, 33, 45, 52, 58 (90% of cervical cancers)
4. CERVAVAC (indigenous quadrivalent): Made by Serum Institute of India

• 9-14 years: 2 doses (0 and 6 months)
• 15-26 years: 3 doses (0, 1-2, 6 months)

---

Cold Chain System in Universal Immunization Programme (Malda)

• Freeze-sensitive vaccines (DPT, DT, TT, HepB, liquid pentavalent): 2-8°C; NEVER freeze
• Freeze-tolerant vaccines (OPV): Can be stored at -15°C to -25°C at higher levels; 2-8°C at district and below

• National/State: Walk-in cold rooms (WICRs) - 2-8°C and walk-in freezers (WIFs) -15 to -25°C; large refrigerators
• District (CMO level): Walk-in cold room or large ILR (Ice-Lined Refrigerator)
• PHC level: Deep freezer (-15 to -25°C) for OPV; Ice-lined refrigerator (ILR) for other vaccines
• Subcentre/Session site: Vaccine carrier with ice packs (maintains 2-8°C for 6-8 hours)

---

SRS Provides Reliable Estimates of Birth and Death in India (Jhargram GMC&H)

• Continuous enumeration by a resident part-time enumerator (REC) in a sample unit (village/urban block)
• Enumerator records ALL births and deaths as they occur
• Retrospective survey by full-time supervisor every 6 months for independent verification
• Dual record system (prospective + retrospective) increases completeness
• About 8,000 sample units; covers both rural and urban areas

1. Dual record system: Cross-checking between continuous enumeration and retrospective survey reduces omissions
2. Large sample: 8000+ sample units nationwide ensures representativeness
3. Rural + urban coverage: Stratified sample represents both settings
4. Regular publication: Annual reports published by Registrar General of India
5. Completeness: >98% completeness for birth and death registration

---

Population Attributable Risk (PAR) (KPC Medical College)

---

Epidemiologically Carrier is More Important Than Cases (Jagannath Gupta)

1. Larger number: For every clinical case, there are many more carriers (e.g., for Typhoid - 1 case: 10 carriers; Diphtheria - silent carriers outnumber cases)
2. Undetected: Carriers have no symptoms, are not isolated, and continue normal activities - spreading disease unknowingly
3. Prolonged shedding: Chronic carriers (e.g., hepatitis B, typhoid - Salmonella typhi in gall bladder) shed organisms for months to years
4. Wider exposure: A carrier moves freely in the community, contacting many more people than a sick case who is usually in bed/hospital
5. Source identification challenge: Cases are identified and treated; carriers remain hidden
6. Epidemiological significance: Major disease transmission in the community comes from carriers, not from visible cases. Hence carrier detection and management is more important epidemiologically.

---

Influenza Vaccine Must be Taken Yearly (NBMC)

1. Antigenic drift: Influenza virus undergoes continuous minor mutations in surface antigens (hemagglutinin and neuraminidase) - "antigenic drift." Annually, the dominant circulating strains change.
2. Annual strain selection: WHO Global Influenza Surveillance and Response System (GISRS) monitors circulating strains worldwide and recommends composition for next season's vaccine (Feb for Northern Hemisphere; Sep for Southern Hemisphere).
3. Waning immunity: Even against the same strain, antibody levels from influenza vaccine wane significantly within 6-12 months.
4. New strains emerging: New subtypes can emerge (H3N2 predominant one year, H1N1 the next).
5. Practical implication: The vaccine administered this year may not match next year's dominant circulating strain. Annual vaccination ensures protection against currently circulating strains.

---

Purpose of Vaccination - Not Only Individual but Community Protection (ESI Joka)

• When a sufficient proportion of the population is immune (through vaccination or natural infection), the pathogen cannot sustain transmission chains in the community
• Even unvaccinated individuals are indirectly protected because the pathogen rarely reaches them
• Herd Immunity Threshold (HIT) = 1 - (1/R0) where R0 is basic reproduction number
  • Measles: R0 = 12-18; HIT = 92-95% (very high vaccination coverage needed)
  • Polio: R0 = 5-7; HIT = 80-85%
  • COVID-19: R0 = 2-4 (original strain); HIT = 50-75%

1. Protects those who cannot be vaccinated: Immunocompromised, infants too young for vaccine, pregnant women (some vaccines contraindicated)
2. Can lead to elimination and eradication of disease (as with smallpox, polio)
3. Protects communities even if individual coverage is incomplete (as long as threshold is met)

---

Monitoring and Surveillance are Not Synonymous (Jhargram GMC&H)

---

Informed Consent in Epidemiological Research (North Bengal Medical College)

1. Information: Participant must be told - study purpose, procedures, risks, benefits, alternatives, voluntary nature, right to withdraw
2. Comprehension: Information must be in participant's language and at their educational level
3. Voluntariness: Free from coercion, undue influence, or pressure
4. Competence: Participant must be mentally competent (special provisions for minors, illiterate - use LAR - Legally Authorized Representative)
5. Documentation: Written consent form signed by participant and witness; copy given to participant

1. Ethical obligation (Belmont Principles: Respect for persons, Beneficence, Justice)
2. Legal requirement (ICMR National Ethical Guidelines 2017)
3. Confidentiality must be assured - especially important in sensitive diseases (HIV, mental health)
4. Participants have right to withdraw without penalty

---

Source and Reservoir of Disease are Not the Same (PC Sen)

• Example: Contaminated water (cholera source), an infectious TB patient's cough droplets (TB source)

• Example: Humans are the reservoir for typhoid; Rodents are the reservoir for plague; Soil is the reservoir for tetanus and anthrax

• The reservoir is where the agent LIVES and MULTIPLIES (ecological niche)
• The source is where the agent COMES FROM immediately before infecting the host

• Reservoir: Chronic human carriers (agent lives in gall bladder)
• Source: Water contaminated by carrier's excreta, or contaminated food handled by a carrier
• A carrier IS both reservoir AND source; but water is only a source (agent cannot replicate in water)

• Reservoir: Wild/domestic dogs, bats, foxes
• Source: Saliva of rabid animal (bite)

---

5 F's in Transmission of Fecal-Oral Diseases (PC Sen)

1. Fluids (Water): Contaminated drinking water - major vehicle for cholera, typhoid, polio, hepatitis A
2. Fingers: Unwashed hands contaminated with feces; direct fecal-oral route - important for diarrhea, hepatitis A, typhoid
3. Foods: Contaminated food (prepared/handled by carriers, irrigated with sewage) - salmonella, shigella, E. coli, hepatitis A
4. Flies: Mechanical transmission of fecal organisms to food/water - feces → fly → food → mouth; relevant for typhoid, cholera, dysentery
5. Fomites: Contaminated surfaces/objects (door handles, money, utensils) touched by contaminated hands

• Safe water supply (break the water route)
• Handwashing with soap (break the finger/hands route)
• Food hygiene and cooking (break the food route)
• Fly control (break the fly route)
• Environmental sanitation/ODF (reduce fecal contamination at source)

---

Standard Error (Midnapore)

1. Measures precision of sample estimate - smaller SE = more precise estimate
2. Used to calculate confidence intervals: 95% CI = Mean ± 1.96 × SE
3. Larger sample size → smaller SE → more precise estimate
4. SE decreases as n increases (inversely proportional to √n)
5. Used in hypothesis testing (t-test, z-test use SE in denominator)

• SD measures spread/variability of individual observations in a sample
• SE measures variability of the sample statistic (mean) across multiple samples of the same size

---

Case Fatality Rate is a Misnomer (SCCMCH)

1. It is NOT a rate: A rate requires a time dimension (events per unit time). CFR has no time dimension - it is a proportion (deaths/cases expressed as percentage).
2. It is NOT truly a fatality "rate": It does not measure the velocity of dying over time; it measures the probability of dying given that one has the disease.
3. Correct terminology: It should be called "Case Fatality Ratio" or "Case Fatality Proportion" (case fatality ratio is now the preferred term by IEA).

1. Measures disease severity/virulence: High CFR = more lethal disease (Ebola CFR ~50%; COVID-19 ~1%)
2. Monitoring of healthcare quality: Decreasing CFR for a disease may indicate improving management
3. Comparing severity of different strains/outbreaks

1. Dependent on case ascertainment - if mild cases are missed, CFR is artificially high
2. Denominator (cases) is often an undercount (iceberg phenomenon)
3. Varies with quality of care, age of cases, strain virulence

---

Random Sampling is Preferred Over Convenience Sampling (MCK)

1. Representativeness: Random sample is more likely to represent the target population; minimizes selection bias
2. Generalizability: Results can be extrapolated to the parent population with known confidence
3. Probability theory applies: Allows calculation of sampling error, confidence intervals, and p-values
4. Validity of statistical tests: Most statistical inference (t-tests, chi-square, regression) requires probability sampling
5. Convenience sampling disadvantages: Systematic selection bias; results cannot be generalized; unrepresentative sample (e.g., only severe/hospitalized cases if sampled from hospital OPD)

---